Navigation Links
Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
Date:12/14/2009

SAN DIEGO, Dec. 14 /PRNewswire/ -- Pfenex Inc. announced today that it has granted Merck & Co., Inc., through an affiliate, an exclusive worldwide license to Pfenex Expression Technology(TM) Pseudomonas-based recombinant protein expression technology for the production of specific proteins to be used in the development of an undisclosed vaccine candidate.

Under the terms of the agreement Pfenex is eligible to receive approximately $52 million in upfront and milestone payments as well as additional royalty payments on any product sales derived from the agreement. This license represents the second commercial license Merck has been granted to Pfenex Expression Technology(TM).

Merck and Pfenex scientists will collaborate on developing the production strains that will be used to express clinically relevant antigens in support of the preclinical and clinical development of the vaccine candidate. The agreement also includes non-exclusive rights for the production of proteins for diagnostic applications.

"We are pleased to be partnering with Merck," said Bertrand C. Liang, CEO of Pfenex, "This collaboration is a clear example of the strength of the Pfenex Expression Technology being leveraged in the discovery, development and production of novel vaccines."

About Pfenex

Pfenex is a protein production company leveraging the unique and powerful Pfenex Expression Technology(TM) platform based on the micro-organism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

SOURCE Pfenex Inc.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
2. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
3. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
4. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
5. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
6. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
7. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
8. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
11. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017   Synthetic Biologics, Inc. (NYSE ... designed to preserve the microbiome to protect and ... to initiate a Phase 2b/3 adaptive pivotal trial ... lactone designed to reduce methane production by certain ... to treat the underlying cause of irritable bowel ...
(Date:1/18/2017)...  Aprima Medical Software, a leading provider of ... and revenue cycle management (RCM) solutions for medical ... reseller Healthcare Data Solutions (HDS) of Coral Cables, ... assume full support for HDS,s customers, which include ... 15 states. Financial terms were not disclosed. ...
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but ... patient. Dentists have several general anesthesia alternatives and finding the right option can result ... College in Tokyo, Japan wanted to find out which anesthetic was the better choice ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
Breaking Medicine News(10 mins):